Sangamo Therapeutics (SGMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 581 | 18,306 | 6,437 | 7,551 | 49,412 |
| Gross Profit | 581 | 18,306 | 6,437 | 7,551 | 49,412 |
| Operating Expenses | 36,134 | 36,161 | 36,065 | 33,541 | 38,781 |
| Operating Income | -35,553 | -17,855 | -29,628 | -25,990 | 10,631 |
| Other Income | 462 | -2,104 | -850 | 2,167 | 129 |
| Pre-tax Income | -35,091 | -19,959 | -30,478 | -23,823 | 10,760 |
| Income Tax | -161 | 27 | 119 | -427 | 88 |
| Net Income Continuous | -34,930 | -19,986 | -30,597 | -23,396 | 10,672 |
| Net Income | $-34,930 | $-19,986 | $-30,597 | $-23,396 | $10,672 |
| EPS Basic Total Ops | -0.11 | -0.08 | -0.14 | -0.09 | 0.05 |
| EPS Basic Continuous Ops | -0.11 | -0.08 | -0.14 | -0.09 | 0.05 |
| EPS Diluted Total Ops | -0.11 | -0.08 | -0.14 | -0.08 | 0.04 |
| EPS Diluted Continuous Ops | -0.11 | -0.08 | -0.14 | -0.09 | 0.05 |
| EPS Diluted Before Non-Recurring Items | -0.11 | -0.08 | -0.14 | -0.11 | 0.04 |
| EBITDA(a) | $-33,655 | $-15,958 | $-27,704 | $-23,855 | $12,758 |